0.1401
16-1月-25 16:45:00
15 分の遅延
株式
-0.0126
-8.25%
本日の幅
0.1395 - 0.1506
ISIN
N/A
ソース
NASDAQ
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers
03 2 2022 08:30:00 提供 Nasdaq GlobeNewswire
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
17 12 2021 08:00:00 提供 Nasdaq GlobeNewswire
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting
11 12 2021 15:30:00 提供 Nasdaq GlobeNewswire
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma
07 12 2021 08:00:01 提供 Nasdaq GlobeNewswire